title: Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study.
abstract: The aim of this single-center, retrospective study was to investigate the impact of rituximab, reconsider the validity of International Prognostic Index (IPI), and evaluate the prognostic role of the cell of origin (CoO) in a relatively young cohort. Three hundred twelve diffuse large B cell lymphoma patients (median age: 52) were included. Rituximab significantly improved the 3- and 5-year progression free survival (PFS) (70% versus 65% and 41% versus 36%, resp.; P < 0.001) but led only to a slight, insignificant increase in 3- and 5-year overall survival (OS) (71% versus 77.3% and %67 versus 74.5%, resp.; P = 0.264). In the young, low risk patient subgroup (aaIPI = 0&1; n = 129), rituximab improved 3- and 5-year PFS and OS rates (P < 0.001 and P = 0.048, resp.). The efficacy of rituximab in young high risk patients was comparable to the literature. CoO data were available in 190 patients. The OS at 3 years was 79% for GC and 64% for non-GC subgroups (P = 0.014). To the best of our knowledge, this is the first study which investigated the impact of R-CHOP in the context of CoO and IPI in a relatively young cohort. CoO was not an independent risk factor for prognosis in the multivariate analysis although patients with GC showed a significant survival advantage in the univariate analysis. CoO was also found to be a significant determinant of response in refractory/relapsed patients. Our results confirm the efficacy of rituximab in low and high risk, young patients outside of a randomized clinical trial setting.
authors: Division of Haematology, Department of Internal Medicine, Istanbul University, Cerrahpasa Medical Faculty, Cerrahpasa Cd., No. 181, Kocamustafapasa-Fatih, 34098 Istanbul, Turkey.
authors: Murat
authors: M
authors: Ozbalak
authors: M Cem
authors: MC
authors: Ar
authors: Nukhet
authors: N
authors: Tuzuner
authors: Ayse
authors: A
authors: Salihoglu
authors: A Emre
authors: AE
authors: Eskazan
authors: Seniz
authors: S
authors: Ongoren Aydin
authors: Zafer
authors: Z
authors: Baslar
authors: Teoman
authors: T
authors: Soysal
authors: Yildiz
authors: Y
authors: Aydin
authors: Anil
authors: A
authors: Barak Dolgun
authors: Onder
authors: O
authors: Ergonul
authors: Burhan
authors: B
authors: Ferhanoglu
references: J Clin Oncol. 1989 Nov;7(11):1630-6
references: 2809679
references: Cancer Sci. 2009 Oct;100(10):1842-7
references: 19656156
references: Leuk Lymphoma. 2008 Mar;49(3):462-9
references: 18297522
references: J Clin Oncol. 2008 Jul 1;26(19):3166-75
references: 18490650
references: Blood. 2003 Jun 1;101(11):4279-84
references: 12576316
references: Am J Surg Pathol. 2004 Apr;28(4):464-70
references: 15087665
references: Ann Oncol. 2010 Jul;21(7):1486-1491
references: 19920060
references: Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):23-32
references: 21454187
references: Haematologica. 2009 Sep;94(9):1250-8
references: 19586937
references: Hematology. 2009 Apr;14(2):84-9
references: 19298719
references: Clin Lymphoma Myeloma Leuk. 2012 Feb;12(1):32-7
references: 22138101
references: Hematology. 2013 Mar;18(2):74-80
references: 23320957
references: Am J Clin Oncol. 1982 Dec;5(6):649-55
references: 7165009
references: Ann Oncol. 2010 Nov;21(11):2255-2261
references: 20444844
references: J Clin Oncol. 2011 Nov 1;29(31):4079-87
references: 21947824
references: Nature. 2000 Feb 3;403(6769):503-11
references: 10676951
references: N Engl J Med. 2002 Jun 20;346(25):1937-47
references: 12075054
references: J Clin Oncol. 2005 Aug 1;23(22):5027-33
references: 15955905
references: Am J Hematol. 2010 Nov;85(11):896-9
references: 20842639
references: Korean J Intern Med. 2010 Sep;25(3):301-8
references: 20830228
references: Hum Pathol. 2008 Jun;39(6):875-84
references: 18440593
references: Blood. 2007 Mar 1;109(5):1857-61
references: 17105812
references: Ann Oncol. 2007 May;18(5):931-9
references: 17395602
references: N Engl J Med. 2002 Jan 24;346(4):235-42
references: 11807147
references: Leuk Lymphoma. 2008 Sep;49(9):1745-51
references: 18798109
references: Lancet Oncol. 2006 May;7(5):379-91
references: 16648042
references: Lancet Oncol. 2008 May;9(5):435-44
references: 18400558
references: Haematologica. 2006 May;91(5):715-6
references: 16670080
references: Blood. 2004 Jan 1;103(1):275-82
references: 14504078
references: N Engl J Med. 1993 Sep 30;329(14):987-94
references: 8141877